PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
178.96%
R&D growth above 1.5x AXSM's 10.62%. Michael Burry would check for spending discipline.
203.49%
G&A change of 203.49% while AXSM maintains overhead. Bruce Berkowitz would investigate efficiency.
No Data
No Data available this quarter, please select a different quarter.
-29.56%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
185.87%
Operating expenses growth above 1.5x AXSM's 6.62%. Michael Burry would check for inefficiency.
185.87%
Total costs growth above 1.5x AXSM's 8.31%. Michael Burry would check for inefficiency.
-0.66%
Interest expense reduction while AXSM shows 24.56% growth. Joel Greenblatt would examine advantage.
-29.56%
Both companies reducing D&A. Martin Whitman would check industry patterns.
-185.91%
EBITDA decline while AXSM shows 35.57% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-185.87%
Operating income decline while AXSM shows 35.57% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
15.24%
Other expenses growth while AXSM reduces costs. John Neff would investigate differences.
-92.79%
Pre-tax income decline while AXSM shows 17.64% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-0.66%
Tax expense reduction while AXSM shows 0.00% growth. Joel Greenblatt would examine advantage.
-92.79%
Net income decline while AXSM shows 19.26% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-3998.91%
EPS decline while AXSM shows 20.49% growth. Joel Greenblatt would examine position.
-3998.91%
Diluted EPS decline while AXSM shows 20.49% growth. Joel Greenblatt would examine position.
-95.29%
Share count reduction while AXSM shows 1.17% change. Joel Greenblatt would examine strategy.
-95.29%
Diluted share reduction while AXSM shows 1.17% change. Joel Greenblatt would examine strategy.